Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) Research & Development: 2019-2024

Historic Research & Development for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to $45.7 million.

  • GeneDx Holdings' Research & Development rose 69.99% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 27.36%. This contributed to the annual value of $45.7 million for FY2024, which is 21.53% down from last year.
  • As of FY2024, GeneDx Holdings' Research & Development stood at $45.7 million, which was down 21.53% from $58.3 million recorded in FY2023.
  • GeneDx Holdings' Research & Development's 5-year high stood at $105.2 million during FY2021, with a 5-year trough of $45.7 million in FY2024.
  • Moreover, its 3-year median value for Research & Development was $58.3 million (2023), whereas its average is $63.4 million.
  • Per our database at Business Quant, GeneDx Holdings' Research & Development surged by 108.25% in 2020 and then slumped by 32.41% in 2023.
  • GeneDx Holdings' Research & Development (Yearly) stood at $72.7 million in 2020, then soared by 44.65% to $105.2 million in 2021, then declined by 18.03% to $86.2 million in 2022, then slumped by 32.41% to $58.3 million in 2023, then declined by 21.53% to $45.7 million in 2024.